Double Blind RCT to Evaluate the Effect of Botulinum Toxin in Raynaud Phenomenon

Led by Emory University · Updated on 2026-07-29

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe. Sometimes it can be refractory to treatments. The goal of this study is to evaluate the efficacy of Botulinum toxin (BT) in the treatment of treatment refractory RP by objective and subjective measures.

CONDITIONS

Brief Title

Botulinum Toxin in Raynaud's Phenomenon

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

Inclusion Criteria:

Age 18 or older
Patients with moderate to severe RP that is not controlled after 3 months of standard medical therapy as prescribed by a Rheumatologist, or severe RP with evidence of tissue loss.

Exclusion Criteria:

Patients under the age of 18
Patients who have previously undergone treatment with BT for RP within the past year
Patients with active infection at the treatment site (active infection defined as cellulitis, purulence, fever, chills, or presence of elevated inflammatory markers, ie. WBC, ESR, CRP)
Patients who have undergone prior digital sympathectomy surgery for RP
Patients who have recently altered their medical regimen for RP within the past 4 weeks
Patients with allergy or contraindication to BT injection

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Double Blind RCT to Evaluate the Effect of Botulinum Toxin in Raynaud Phenomenon

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria